MT-125

DRUG2 trials

Sponsors

Myosin Therapeutics Inc.

Conditions

GlioblastomaGlioblastoma (GBM)

Phase 1

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

RecruitingNCT07185880

Myosin Therapeutics Inc.Glioblastoma (GBM)

Start: 2026-04-01End: 2032-02-01Target: 36Updated: 2026-04-14

A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

Not yet recruitingNCT07604285

Myosin Therapeutics Inc.Glioblastoma

Start: 2026-07-01End: 2027-03-01Target: 36Updated: 2026-05-22